Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 9 » default
Therapeutics and Clinical Risk Management
ISSN: 1178-203X
- View all (2241)
- Volume 19, 2023 (24)
- Volume 18, 2022 (104)
- Volume 17, 2021 (134)
- Volume 16, 2020 (134)
- Volume 15, 2019 (154)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Archive: Volume 9, 2013
Colchicine intoxication: a report of two suicide cases
Erden A, Karagoz H, Gümüscü HH, Karahan S, Basak M, Aykas F, Bulut K, Cetinkaya A, Avci D, Poyrazoglu OK
Therapeutics and Clinical Risk Management 2013, 9:505-509
Published Date: 5 December 2013
National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool
Ramli A, Aljunid SM, Sulong S, Md Yusof FA
Therapeutics and Clinical Risk Management 2013, 9:491-504
Published Date: 4 December 2013
Pseudobulbar affect: prevalence and management
Ahmed A, Simmons Z
Therapeutics and Clinical Risk Management 2013, 9:483-489
Published Date: 29 November 2013
Treatment of bisphosphonate related osteonecrosis following root canal therapy at the 1-year follow-up: report of two cases
Kaptan F, Kazandag MK, Iseri U
Therapeutics and Clinical Risk Management 2013, 9:477-482
Published Date: 2 December 2013
Gabapentin enacarbil extended release for the treatment of postherpetic neuralgia in adults
Thomas BM, Farquhar-Smith P
Therapeutics and Clinical Risk Management 2013, 9:469-475
Published Date: 25 November 2013
Sampling times and genotyping concerns in bioequivalence evaluation of branded and generic formulations
Zhao XY, Xu HM, Zhou Q
Therapeutics and Clinical Risk Management 2013, 9:463-468
Published Date: 25 November 2013
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study
Rossi L, Tomao F, Lo Russo G, Papa A, Zoratto F, Marzano R, Basso E, Giordani E, Verrico M, Ricci F, Pasciuti G, Francini E, Tomao S
Therapeutics and Clinical Risk Management 2013, 9:457-462
Published Date: 11 November 2013
Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
Freeman HJ
Therapeutics and Clinical Risk Management 2013, 9:451-456
Published Date: 7 November 2013
Treatment approaches and antibiotic use for emergency dental treatment in Turkey
Kaptan RF, Haznedaroglu F, Basturk FB, Kayahan MB
Therapeutics and Clinical Risk Management 2013, 9:443-449
Published Date: 7 November 2013
Guidelines for overcoming hospital managerial challenges: a systematic literature review
Crema M, Verbano C
Therapeutics and Clinical Risk Management 2013, 9:427-441
Published Date: 31 October 2013
Analysis of the metabolic properties of maintenance hemodialysis patients with glucose-added dialysis based on high performance liquid chromatography quadrupole time-of-flight mass spectrometry
Cui L, Meng Y, Xu D, Feng YY, Chen GY, Hu B, Feng GJ, Yin LH
Therapeutics and Clinical Risk Management 2013, 9:417-425
Published Date: 29 October 2013
Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients
Stonecipher KG, Chia J, Onyenwenyi A, Villanueva L, Hollander DA
Therapeutics and Clinical Risk Management 2013, 9:409-415
Published Date: 25 October 2013
Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
Yilmaz S, Simsek I
Therapeutics and Clinical Risk Management 2013, 9:403-408
Published Date: 25 October 2013
Eliminating the need for fasting with oral administration of bisphosphonates
Pazianas M, Abrahamsen B, Ferrari S, Russell RGG
Therapeutics and Clinical Risk Management 2013, 9:395-402
Published Date: 18 October 2013
Resolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularization
Petrou P, Georgalas I, Markomichelakis N, Vergados I, Gianakaki E, Rouvas A
Therapeutics and Clinical Risk Management 2013, 9:391-394
Published Date: 18 October 2013
Obesity detection rate among primary school students in the People's Republic of China: a meta-analysis
Jin Y, Ding L, Yao Y, Song X, Tang H, He L, Chen Y
Therapeutics and Clinical Risk Management 2013, 9:383-390
Published Date: 11 October 2013
A 6-year experience of CPR outcomes in an emergency department in Thailand
Sittichanbuncha Y, Prachanukool T, Sawanyawisuth K
Therapeutics and Clinical Risk Management 2013, 9:377-381
Published Date: 8 October 2013
Randomized controlled study of the antipyretic efficacy of oral paracetamol, intravenous paracetamol, and intramuscular diclofenac in patients presenting with fever to the emergency department
Paramba FC, Naushad VA, Purayil N, Mohammed OH, Chandra P
Therapeutics and Clinical Risk Management 2013, 9:371-376
Published Date: 3 October 2013
Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?
Havla J, Kleiter I, Kümpfel T
Therapeutics and Clinical Risk Management 2013, 9:361-369
Published Date: 3 October 2013
The effect of eradicating Helicobacter pylori on idiopathic central serous chorioretinopathy patients
Dang Y, Mu Y, Zhao M, Li L, Guo Y, Zhu Y
Therapeutics and Clinical Risk Management 2013, 9:355-360
Published Date: 2 September 2013
Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
D’Urzo A
Therapeutics and Clinical Risk Management 2013, 9:341-353
Published Date: 19 August 2013
Options for treating postherpetic neuralgia in the medically complicated patient
Bruckenthal P, Barkin RL
Therapeutics and Clinical Risk Management 2013, 9:329-340
Published Date: 19 August 2013
A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia
Caccia S, Invernizzi RW, Nobili A, Pasina L
Therapeutics and Clinical Risk Management 2013, 9:319-328
Published Date: 8 August 2013
Potential therapeutic hazards due to drug–drug interaction between topically and systemically coadministered medications
Lan MJ, Zhou Q
Therapeutics and Clinical Risk Management 2013, 9:313-317
Published Date: 30 July 2013
Comparative pharmacokinetic and pharmacodynamic evaluation of branded and generic formulations of meloxicam in healthy male volunteers
Del Tacca M, Pasqualetti G, Gori G, Pepe P, Di Paolo A, Lastella M, De Negri F, Blandizzi C
Therapeutics and Clinical Risk Management 2013, 9:303-311
Published Date: 24 July 2013
Anesthesia and postoperative analgesia during unilateral lower-extremity fracture surgeries using multiple injections through catheters beside the lumbar plexus or sciatic nerve
Zhang X, Zhou Y, Chen L, Wang Q, Ni J, Liu L, Hu C, Xu X
Therapeutics and Clinical Risk Management 2013, 9:299-302
Published Date: 23 July 2013
Two cases of jugular vein thrombosis in severely burned patients
Cen H, He X
Therapeutics and Clinical Risk Management 2013, 9:295-297
Published Date: 15 July 2013
New drug classes for the treatment of partial onset epilepsy: focus on perampanel
Shih JJ, Tatum WO, Rudzinski LA
Therapeutics and Clinical Risk Management 2013, 9:285-293
Published Date: 8 July 2013
Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center
Anger KE, DeGrado JR, Greenwood BC, Cohen SA, Szumita PM
Therapeutics and Clinical Risk Management 2013, 9:277-284
Published Date: 5 June 2013
Intervention for improving the appropriateness of physician orders for oral medications in geriatric VIP patients during the journey to JCI accreditation
Zhu LL, Zhou Q
Therapeutics and Clinical Risk Management 2013, 9:273-275
Published Date: 28 May 2013
Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management
Li W, Zeng S, Yu LS, Zhou Q
Therapeutics and Clinical Risk Management 2013, 9:259-271
Published Date: 27 May 2013
Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability
Pan CY, Wang XL
Therapeutics and Clinical Risk Management 2013, 9:247-257
Published Date: 24 May 2013
Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents
Citrome L
Therapeutics and Clinical Risk Management 2013, 9:235-245
Published Date: 20 May 2013
Current sedation practice among general dental practitioners and dental specialists in Jordan: an example of a developing country
Al-Shayyab MH, Ryalat S, Dar-odeh N, Alsoleihat F
Therapeutics and Clinical Risk Management 2013, 9:223-233
Published Date: 14 May 2013
Clinically significant interactions between antiretroviral and co-prescribed drugs for HIV-infected children: profiling and comparison of two drug databases
Oshikoya KA, Oreagba IA, Ogunleye OO, Lawal S, Senbanjo IO
Therapeutics and Clinical Risk Management 2013, 9:215-221
Published Date: 14 May 2013
Investigation of the impact of urine handling procedures on interpretation of urinalysis findings and product safety in subjects treated with ezogabine
Brickel N, DeRossett S, Buraglio M, Evans C, Jones S
Therapeutics and Clinical Risk Management 2013, 9:207-213
Published Date: 7 May 2013
Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria
Sadaba B, Azanza JR, Gomez-Guiu A, Rodil R
Therapeutics and Clinical Risk Management 2013, 9:197-205
Published Date: 3 May 2013
Case of femoral diaphyseal stress fracture after long-term risedronate administration diagnosed by iliac bone biopsy
Nagai T, Sakamoto K, Ishikawa K, Saito E, Kuroda T, Inagaki K
Therapeutics and Clinical Risk Management 2013, 9:191-195
Published Date: 30 April 2013
An update of teriflunomide for treatment of multiple sclerosis
Oh J, O'Connor PW
Therapeutics and Clinical Risk Management 2013, 9:177-190
Published Date: 26 April 2013
Vitamin D reduces falls and hip fractures in vascular Parkinsonism but not in Parkinson’s disease
Sato Y, Iwamoto J, Honda Y, Amano N
Therapeutics and Clinical Risk Management 2013, 9:171-176
Published Date: 22 April 2013
New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
Andersson KE
Therapeutics and Clinical Risk Management 2013, 9:161-170
Published Date: 18 April 2013
Tolerability of diclofenac sodium 1% gel with concomitant medications known to interact with diclofenac
Peniston JH, Gold MS, Wieman MS, Alwine LK
Therapeutics and Clinical Risk Management 2013, 9:153-159
Published Date: 16 April 2013
Bioequivalence evaluation of epinephrine autoinjectors with attention to rapid delivery
Sclar DA
Therapeutics and Clinical Risk Management 2013, 9:149-151
Published Date: 12 April 2013
Clinical development of neridronate: potential for new applications
Gatti D, Rossini M, Viapiana O, Idolazzi L, Adami S
Therapeutics and Clinical Risk Management 2013, 9:139-147
Published Date: 3 April 2013
Associations between body mass index and molecular subtypes as well as other clinical characteristics of breast cancer in Chinese women
Chen FY, Ou HY, Wang SM, Wu YH, Yan GJ, Tang LL
Therapeutics and Clinical Risk Management 2013, 9:131-137
Published Date: 26 March 2013
Sustained treatment effect in attention-deficit/hyperactivity disorder: focus on long-term placebo-controlled randomized maintenance withdrawal and open-label studies
Goodman DW
Therapeutics and Clinical Risk Management 2013, 9:121-130
Published Date: 21 March 2013
Prescription pattern and prevalence of potentially inappropriate medications among elderly patients in a Nigerian rural tertiary hospital
Fadare JO, Agboola SM, Opeke OA, Alabi RA
Therapeutics and Clinical Risk Management 2013, 9:115-120
Published Date: 13 March 2013
Prospective, double-blind, randomized controlled trial of electrophysiologically guided femoral nerve block in total knee arthroplasty
Youm YS, Cho SD, Hwang CH
Therapeutics and Clinical Risk Management 2013, 9:107-113
Published Date: 11 March 2013
Gender, airborne chemical monitoring, and physical work environment are related to indoor air symptoms among nonindustrial workers in the Klang Valley, Malaysia
Syazwan AI, Hafizan J, Baharudin MR, Azman AZF, Izwyn Z, Zulfadhli I, Syahidatussyakirah K
Therapeutics and Clinical Risk Management 2013, 9:87-105
Published Date: 8 March 2013
Advances in the treatment of relapsing–remitting multiple sclerosis – critical appraisal of fingolimod
Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C
Therapeutics and Clinical Risk Management 2013, 9:73-85
Published Date: 3 March 2013
Safe medication use based on knowledge of information about contraindications concerning cross allergy and comprehensive clinical intervention
Li W, Zhu LL, Zhou Q
Therapeutics and Clinical Risk Management 2013, 9:65-72
Published Date: 26 February 2013
Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication
Blasi F, Tarsia P, Mantero M, Morlacchi LC, Piffer F
Therapeutics and Clinical Risk Management 2013, 9:55-64
Published Date: 12 February 2013
Current and emerging management options for patients with Morquio A syndrome
Algahim MF, Almassi GH
Therapeutics and Clinical Risk Management 2013, 9:45-53
Published Date: 11 February 2013
Prescribing practice and evaluation of appropriateness of enteral nutrition in a university teaching hospital
Zhu XP, Zhu LL, Zhou Q
Therapeutics and Clinical Risk Management 2013, 9:37-43
Published Date: 7 February 2013
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
Paplomata E, O'Regan R
Therapeutics and Clinical Risk Management 2013, 9:27-36
Published Date: 14 January 2013
Diagnosis and management of miliary tuberculosis: current state and future perspectives
Ray S, Talukdar A, Kundu S, Khanra D, Sonthalia N
Therapeutics and Clinical Risk Management 2013, 9:9-26
Published Date: 8 January 2013
Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I
Iwamoto J, Sato Y, Uzawa M, Matsumoto H
Therapeutics and Clinical Risk Management 2013, 9:1-7
Published Date: 28 December 2012